Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
Phase 1
Terminated
- Conditions
- InflammationSystemic Lupus Erythematosus
- Interventions
- Drug: placebo
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01689025
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Houston, Texas, United States
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2HealthyDiabetes
- Interventions
- Drug: placebo
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 107
- Registration Number
- NCT01686945
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT01682902
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Atlanta, Georgia, United States
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 272
- Registration Number
- NCT01680341
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Delivery Systems
- Interventions
- Other: 19 injectionsDrug: sodium chloride 0.9% solution
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 82
- Registration Number
- NCT01680328
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 438
- Registration Number
- NCT01676116
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Presov, Slovakia
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 346
- Registration Number
- NCT01664247
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: biphasic human insulin 50Drug: biphasic insulin aspart 50
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 83
- Registration Number
- NCT01650129
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 123
- Registration Number
- NCT01649570
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- InflammationRheumatoid Arthritis
- Interventions
- Drug: placebo
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT01647451
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath